Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2013-03-24
Adverse events
Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-19 (study day 27.0); relationship: PROBABLE
Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2013-04-19 (study day 27.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-19 (study day 27.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-04-19 (study day 27.0); relationship: PROBABLE
Mild HEMIANOPIA HOMONYMOUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-14 (study day 22.0); relationship: NONE
Mild SINUS BRADYCARDIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-19 (study day 57.0); relationship: POSSIBLE
Data queries
No data queries.